Evidence map›Paper›PMID 26300994›Full record

ArticleClinical epigenetics2015

Detection of nasopharyngeal carcinoma in Morocco (North Africa) using a multiplex methylation-specific PCR biomarker assay.

Imran Nawaz, Khalid Moumad, Debora Martorelli, Moulay Mustapha Ennaji, Xiaoying Zhou, Zhe Zhang, Riccardo Dolcetti, Meriem Khyatti, Ingemar Ernberg, Li-Fu Hu

Open access · goldAbstract read
In one paragraph

Article in Clinical epigenetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 2 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 30 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Diagnostic Value ofDiagnostics (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Review
  9. Article
  10. Disease markers · 2020
    Article
  11. Article
  12. Article
  13. Article
  14. Diagnostic potential of methylatedCancer management and research · 2018
    Article
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 7 countries.

Imran Nawaz *Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm, SE-17177 Sweden.
Khalid Moumad *Department of Molecular Genetic Epidemiology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.
Debora MartorelliCancer Bio-Immunotherapy Unit Centro di Riferimento Oncologico IRCCS - National Cancer Institute, Via Franco Gallini, 233081 Aviano, PN Italy.
Moulay Mustapha EnnajiUniversity Hassan II, Faculty of Sciences and Techniques, Mohammedia - Casablanca, Laboratory of Virology, Microbiology and Quality/ETB, Mohammedia, , BP 146, 20650 Morocco.
Xiaoying ZhouDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm, SE-17177 Sweden.
Zhe ZhangDepartment of Orolaryngology - Head and Neck Surgery, First Affiliated Hospital of Guangxi Medical University, Guangxi, People's Republic of China.
Riccardo DolcettiCancer Bio-Immunotherapy Unit Centro di Riferimento Oncologico IRCCS - National Cancer Institute, Via Franco Gallini, 233081 Aviano, PN Italy.
Meriem KhyattiOncovirology Laboratory, Institut Pasteur du Maroc, 20360 Casablanca, Morocco.
Ingemar ErnbergDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm, SE-17177 Sweden.
Li-Fu HuDepartment of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Box 280, Stockholm, SE-17177 Sweden.
Karolinska Institutet · SEGerman Cancer Research Center · DEInstitut Pasteur du Maroc · MAIstituti di Ricovero e Cura a Carattere Scientifico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSilencing of tumor suppressor genes (TSGs) or activation of oncogenes by, e.g., aberrant promoter methylation, may be early events during carcinogenesis. The methylation status of such genes can be used for early detection of cancer. We are pursuing this approach in our efforts to develop markers for early detection and follow-up of nasopharyngeal carcinoma (NPC). We set out to develop this approach to allow identification of NPC from Morocco and then also compared with NPC samples from different geographical locations and different ethnicity with different NPC incidences, Epstein-Barr virus (EBV) prevalence, and environments.

resultsBy multiplex methylation-specific PCR (MMSP), multiple relevant genes can be detected simultaneously, to achieve high sensitivity and specificity. The strong association of EBV with NPC is also very useful in such an approach. We have initially screened for 12 potential marker genes including EBV genes coding for EBV nuclear antigen 1 (EBNA1) and latent membrane protein-1 (LMP1) and ten potential TSGs obtained from previously published data. The resulting assay included EBNA1, LMP1, and three cellular TSGs: ITGA9, RASSF1A, and P16. We evaluated this assay on 64 NPC patient biopsies from Morocco, Italy, and China compared to deoxyribonucleic acid (DNA) from 20 nasopharyngeal control tissues. In the Moroccan NPC cohort (n = 44), prevalence of the EBNA1 gene showed the highest sensitivity (36/44; 82 %) with 94 % specificity. Out of eight (18 %) EBNA1 negative Moroccan samples, only three were positive for at least one methylated cellular gene. By detection of cellular marker genes, the sensitivity increased from 82 to 89 % (39/44). In the whole material of 64 biopsies from three geographical locations, at least any one marker (viral or cellular) could be detected in 91 % of biopsies with 90 % specificity. In a pilot evaluating assay performance on serum DNA from NPC and controls including samples from Italy (n = 11) and China (n = 5), at least any one marker from the MMSP assay could be detected in 88 %, but the specificity was only 50 %.

conclusionsAn MMSP assay has the potential for detection of NPC by screening in high-risk populations. Serum-derived DNA seems not as good as earlier published NPC swab DNA for screening purpose.

Indexed as

BiomarkerBisulfite conversionDNA methylationEarly diagnosisMMSPMoroccoNPCScreeningTSGs

Identifiers

PMID26300994
PMCPMC4546349
OpenAlexW1593940291

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.